Werewolf Therapeutics Inc (NASDAQ: HOWL) has entered right into a medical trial collaboration and provide settlement with Merck & Co Inc (NYSE: MRK) to judge WTX-124 together with Keytruda (pembrolizumab).
- WTX-124 is a systemically delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE product candidate.
- The deliberate medical trial can be carried out by Werewolf and is designed to judge the security and preliminary efficacy of WTX-124 as a monotherapy and together with Keytruda in sufferers with stable tumors.
- Werewolf Therapeutics plans to submit an investigational new drug (IND) utility for WTX-124 to the FDA in 1H of 2022.
- Worth Motion: HOWL shares are up 3.70% at $15.10 through the market session on the final examine Wednesday.
© 2021 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.